https://orcid.org/0009-0005-2876-0161
TO THE EDITOR:
Over the past 5 decades, the combination of an anthracycline and cytarabine (“3+7”) remains the standard of care for patients with newly diagnosed acute myeloid leukemia (AML) who are suitable for intensive induction therapy.1 Complete remission (CR) can be achieved in 65% to 75% of younger patients (≤60 years) and in 40% to 60% of older patients (>60 years).2,3 However, patients in the adverse-risk category who received intensive chemotherapy (IC) had significantly lower CR rates and more dismal outcomes than those in favorable- and intermediate-risk categories based on the revised 2017 European LeukemiaNet (ELN) genetic risk stratification. The adverse-risk patients had a disappointing CR rate of 43% to 45% under age of 60.4,5 Venetoclax (VEN), in combination with low-dose cytarabine or hypomethylating agents, has shown safety and efficacy in older patients...
References
1.
Yates
JW
, Wallace
HJ
, Ellison
RR
, Holland
JF
. Cytosine arabinoside (NSC 63878) and daunorubicin (NSC 83142) therapy in acute nonlymphocytic leukemia
. Cancer Chemother Rep
. 1973
;57
(4
):485
-488
.2.
Wiernik
PH
, Banks
PLC
, Case
DC
, et al. Cytarabine plus idarubicin or daunorubicin as induction and consolidation therapy for previously untreated adult patients with acute myeloid leukemia
. Blood
. 1992
;79
(2
):313
-319
.3.
Vogler
WR
, Velez-Garcia
E
, Weiner
RS
, et al. A phase III trial comparing idarubicin and daunorubicin in combination with cytarabine in acute myelogenous leukemia: a Southeastern Cancer Study Group study
. J Clin Oncol
. 1992
;10
(7
):1103
-1111
.4.
Herold
T
, Rothenberg-Thurley
M
, Grunwald
VV
, et al. Validation and refinement of the revised 2017 European LeukemiaNet genetic risk stratification of acute myeloid leukemia
. Leukemia
. 2020
;34
(12
):3161
-3172
.5.
Tyner
JW
, Tognon
CE
, Bottomly
D
, et al. Functional genomic landscape of acute myeloid leukaemia
. Nature
. 2018
;562
(7728
):526
-531
.6.
Wei
AH
, Strickland
SA
, Hou
JZ
, et al. Venetoclax combined with low-dose cytarabine for previously untreated patients with acute myeloid leukemia: results from a phase Ib/II study
. J Clin Oncol
. 2019
;37
(15
):1277
-1284
.7.
DiNardo
CD
, Pratz
K
, Pullarkat
V
, et al. Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia
. Blood
. 2019
;133
(1
):7
-17
.8.
Wei
A
, Montesinos
P
, Ivanov
V
, et al. Venetoclax plus LDAC for patients with untreated AML ineligible for intensive chemotherapy: phase 3 randomized placebo-controlled trial
. Blood
. 2020
;135
(24
):2137
-2145
.9.
DiNardo
CD
, Jonas
BA
, Pullarkat
V
, et al. Azacitidine and venetoclax in previously untreated acute myeloid leukemia
. N Engl J Med
. 2020
;383
(7
):617
-629
.10.
Röllig
C
, Kramer
M
, Schliemann
C
, et al. Does time from diagnosis to treatment affect the prognosis of patients with newly diagnosed acute myeloid leukemia?
. Blood
. 2020
;136
(7
):823
-830
.11.
Burd
A
, Levine
RL
, Ruppert
AS
, et al. Precision medicine treatment in acute myeloid leukemia using prospective genomic profiling: feasibility and preliminary efficacy of the Beat AML Master Trial
. Nat Med
. 2020
;26
(12
):1852
-1858
.12.
Cherry
EM
, Abbott
D
, Amaya
M
, et al. Venetoclax and azacitidine compared with induction chemotherapy for newly diagnosed patients with acute myeloid leukemia
. Blood Adv
. 2021
;5
(24
):5565
-5573
.13.
Venugopal
S
, DiNardo
CD
, Loghavi
S
, et al. Differential prognostic impact of RUNX1 mutations according to frontline therapy in patients with acute myeloid leukemia
. Am J Hematol
. 2022
;97
(12
):1560
-1567
.14.
Stone
RM
, Mandrekar
SJ
, Sanford
BL
, et al. Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation
. N Engl J Med
. 2017
;377
(5
):454
-464
.15.
Pei
S
, Pollyea
DA
, Gustafson
A
, et al. Monocytic subclones confer resistance to venetoclax-based therapy in patients with acute myeloid leukemia
. Cancer Discov
. 2020
;10
(4
):536
-551
.16.
DiNardo
CD
, Lachowiez
CA
, Takahashi
K
, et al. Venetoclax combined with FLAG-IDA induction and consolidation in newly diagnosed and relapsed or refractory acute myeloid leukemia
. J Clin Oncol
. 2021
;39
(25
):2768
-2778
.17.
Wang
H
, Mao
L
, Yang
M
, et al. Venetoclax plus 3 + 7 daunorubicin and cytarabine chemotherapy as first-line treatment for adults with acute myeloid leukaemia: a multicentre, single-arm, phase 2 trial
. Lancet Haematol
. 2022
;9
(6
):e415
-e424
.18.
Ohtake
S
, Miyawaki
S
, Fujita
H
, et al. Randomized study of induction therapy comparing standard-dose idarubicin with high-dose daunorubicin in adult patients with previously untreated acute myeloid leukemia: the JALSGAML201 study
. Blood
. 2011
;117
(8
):2358
-2365
.19.
Fernandez
HF
, Sun
Z
, Yao
X
, et al. Anthracycline dose intensification in acute myeloid leukemia
. N Engl J Med
. 2009
;361
(13
):1249
-1259
.20.
Kadia
TM
, Reville
PK
, Borthakur
G
, et al. Venetoclax plus intensive chemotherapy with cladribine, idarubicin, and cytarabine in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a cohort from a single-centre, single-arm, phase 2 trial
. Lancet Haematol
. 2021
;8
(8
):e552
-e561
.© 2023 by The American Society of Hematology
2023
© 2023 by The American Society of Hematology
2023
You do not currently have access to this content.
This feature is available to Subscribers Only
Sign In or Create an Account Close Modal